Public offering

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
星期三, 三月 20, 2024
Brussels Stock Exchange, SCI, Public, Private, KBC, VWAP, ARC, Hand, Acceleration, Regulation, DSM-IV codes, CSO, Movement, EUR, Private placement, BCI, Offerings, Public offering, Equity carve-out, Euronext, Issue, Euronext Amsterdam, Security (finance)

The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.

Key Points: 
  • The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • “It is the Company’s intention to raise gross proceeds of indicatively EUR 15 million from the Offerings, with an up to EUR 5 million upsize option.
  • A separate announcement will be made shortly regarding the Public Offer in France via the PrimaryBid platform and its terms.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
星期三, 三月 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

LIFT ANNOUNCES MARKETED PUBLIC OFFERING

Retrieved on: 
星期一, 三月 18, 2024
Lithium, Income Tax Act, Public, Private, TSX Venture Exchange, Public offering, Sale, Regulation, WIRE, News, NOT, Person, Prospectus, Agent, NEWS, Security (finance)

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Key Points: 
  • /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
    VANCOUVER, BC, March 18, 2024 /CNW/ - Li-FT Power Ltd. ("LIFT" or the "Company") (TSXV: LIFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce that it has commenced a marketed best efforts public offering (the "Public Offering") of up to 1,179,500 common shares of the Company that will qualify as "flow-through shares" (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) (the "Flow-Through Shares") at a price of $6.05 per Flow-Through Share (the "Offering Price") for aggregate gross proceeds of up to $7,135,975.
  • The Public Offering is being conducted through a syndicate of agents led by Canaccord Genuity Corp. (collectively, the "Agents").
  • The Public Offering will be conducted pursuant to the Company's Canadian base shelf prospectus dated December 22, 2023 (the "Base Shelf Prospectus").
  • The Public Offering and the Non-Brokered Offering are subject to the satisfaction of certain conditions, including receipt of all applicable regulatory approvals including the approval of the TSX Venture Exchange.

Correction of a release from 20.12.2023 19:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024

Retrieved on: 
星期三, 三月 13, 2024
TaTaTu, Public offering, Calendar, Correction

Correction of a release from 20.12.2023 19:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024

Key Points: 
  • Correction of a release from 20.12.2023 19:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • 27 September 2024: Board of Directors, approval of the half-yearly financial statements as at 30 June 2024 as subject to voluntary auditing.
  • This press release and the corporate events calendar are available on the Company's website at the following address https://corporate.tatatu.com/en/corporate/ Investors section/Financial Calendar.

TaTaTu S.p.A.: ALEPH FINANCE APPOINTED NEW LISTING SPONSOR

Retrieved on: 
星期三, 三月 13, 2024
TaTaTu, Public offering, Security (finance)

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN
    Rome, March 7th 2024 - Tatatu S.p.A. (the “Company”) that owns TaTaTu, an entertainment platform based on data sharing economy and circular economy, listed through Direct Listing of shares on Euronext Growth Paris (ticker code: ALTTU), hereby notifies that starting from March 19th 2024, Aleph Finance (trading name of U Capita Asset Management LLP) has been appointed as the new listing sponsor of Tatatu S.p.A replacing Portzamparc BNP Paribas Group.

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Retrieved on: 
星期三, 一月 31, 2024
EDGAR, SAN, Indian stock exchange, Form S-1, Warrant, Telephone, Public, Exercise, Prospectus, TSX, ATTN:, Private placement, Public offering, Suite, Private, Toronto Stock Exchange, Form, Security (finance)

Aptose also announced the closing of the previously announced US $4 million private placement (the “Private Placement”) of Common Shares with Hanmi Pharmaceutical, Inc. (“Hanmi”), Seoul, South Korea, yielding ownership of 19.03% of the outstanding Common Shares of the Company.

Key Points: 
  • Aptose also announced the closing of the previously announced US $4 million private placement (the “Private Placement”) of Common Shares with Hanmi Pharmaceutical, Inc. (“Hanmi”), Seoul, South Korea, yielding ownership of 19.03% of the outstanding Common Shares of the Company.
  • Total gross proceeds from the public offering and private placement were approximately $13.7 million, excluding underwriting discounts, placement agent commissions and other offering-related expenses.
  • The total number of Common Shares outstanding after the closing of the Public Offering, including the Over-Allotment Option, and Private Placement is 15,706,810 and warrants outstanding are 8,332,163.
  • Newbridge Securities Corporation acted as the sole book-running manager for the Public Offering and as placement agent for the Private Placement.

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Retrieved on: 
星期五, 一月 26, 2024
Private, Private placement, SAN, Form S-1, Public offering, Toronto Stock Exchange, Prospectus, Form, EDGAR, Sale, Indian stock exchange, Public, Suite, TSX, ATTN:, Telephone, Security (finance)

Gross proceeds from the Public Offering, before deducting underwriting discounts and commissions and offering expenses payable by Aptose, are expected to be approximately US $8.4 million.

Key Points: 
  • Gross proceeds from the Public Offering, before deducting underwriting discounts and commissions and offering expenses payable by Aptose, are expected to be approximately US $8.4 million.
  • Aptose also announced the pricing of a concurrent $4 million private placement (the “Private Placement”) of Common Shares with Hanmi Pharmaceutical, Inc. (“Hanmi”), Seoul, South Korea, representing ownership of 19.97% of the outstanding Common Shares of the Company following the Private Placement.
  • Newbridge Securities Corporation is acting as the sole book-running manager for the Public Offering and as placement agent for the Private Placement.
  • The Public Offering and Private Placement are subject to the approval of the Toronto Stock Exchange (“TSX”) and Nasdaq.

TaTaTu S.p.A.: TERMINATION OF THE LIQUIDITY CONTRACT DATED 09/22/2022 WITH EXANE AND IMPLEMENTATION OF A NEW CONTRACT OF LIQUIDITY WITH KEPLER CHEUVREUX

Retrieved on: 
星期三, 一月 3, 2024
TaTaTu, Council, Euronext Paris, Agreement, MAR, Liquidity, European, Public offering, European Parliament, Calendar, Commercial code, AMF

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Tatau S.p.A, and Kepler Cheuvreux (the “New Liquidity Provider”) have signed on December 21, 2023 a liquidity contract regarding the liquidity of Tatatu S.p.A shares admitted to Euronext Paris (the “Agreement”).
  • The implementation of the Agreement will be carried out in accordance with the legal provisions in force, and more specifically with the provisions of Regulation (EU) No.
  • This press release and the corporate events calendar are available on the Company's website at the following address https://corporate.tatatu.com/en/corporate/ Investors section/Financial Calendar.

TaTaTu S.p.A.: FINANCIAL CALENDAR 2024

Retrieved on: 
星期三, 十二月 20, 2023
TaTaTu, Calendar, Public offering, Regulatory News Service

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • 27 September 2024: Board of Directors, approval of the half-yearly financial statements as at 30 June 2024 as subject to voluntary auditing.
  • Any amendment to the above schedule will be promptly communicated to the market.
  • This press release and the corporate events calendar are available on the Company's website at the following address https://corporate.tatatu.com/en/corporate/ Investors section/Financial Calendar.

Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
星期二, 十月 31, 2023
Sale, Public offering, Toronto Stock Exchange, EDGAR, News, Private, Option, Investissement Québec, Initial public offering, Indian stock exchange, Public, TSX, Security (finance)

MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public Offering”) of 12,500,000 common shares of the Company (the “Common Shares”) at a public offering price of US$1.00 per Common Share (the “Offering Price”).

Key Points: 
  • MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public Offering”) of 12,500,000 common shares of the Company (the “Common Shares”) at a public offering price of US$1.00 per Common Share (the “Offering Price”).
  • The gross proceeds of the Public Offering are US$12,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses.
  • As at the date of closing, Investissement Québec beneficially owns approximately 19.9% (25.4% if the Exchangeable Subscription Receipts were to be exchanged into Common Shares) of the issued and outstanding Common Shares.
  • The Public Offering and the Concurrent Private Placement are subject to final acceptance of the Toronto Stock Exchange.